High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study

被引：22

作者：

Reyes, Henry D. ^{[1
]}

Miecznikowski, Jeffrey ^{[2
]}

Gonzalez-Bosquet, Jesus ^{[1
]}

Devor, Eric J. ^{[1
]}

Zhang, Yuping ^{[1
]}

Thiel, Kristina W. ^{[1
]}

Samuelson, Megan I. ^{[3
]}

McDonald, Megan ^{[1
]}

Stephan, Jean-Marie ^{[1
]}

Hanjani, Parviz ^{[4
]}

Guntupalli, Saketh ^{[5
]}

Tewari, Krishnansu S. ^{[6
]}

Backes, Floor ^{[7
]}

Ramirez, Nilsa ^{[8
]}

Fleming, Gini F. ^{[9
]}

Filiaci, Virginia ^{[10
]}

Birrer, Michael J. ^{[11
]}

Leslie, Kimberly K. ^{[1
]}

机构：

[1] Univ Iowa, Holden Comprehens Canc Ctr, Dept Obstet & Gynecol, Iowa City, IA 52242 USA

[2] SUNY Univ Buffalo, Dept Biostat, Buffalo, NY USA

[3] Univ Iowa, Holden Comprehens Canc Ctr, Dept Pathol, Iowa City, IA 52242 USA

[4] Abington Mem Hosp, Dept Gynecol Oncol, Hanjani Inst Gynecol Oncol, Abington, PA 19001 USA

[5] Univ Colorado Denver, Dept Obstet & Gynecol, Aurora, CO USA

[6] Univ Calif Irvine, Med Ctr, Div Gynecol Oncol, Orange, CA USA

[7] Ohio State Univ, Med Ctr, Dept Div Obstet & Gynecol, Columbus, OH 43210 USA

[8] Nationwide Childrens Hosp, Res Inst, Dept Pathol, Columbus, OH USA

[9] Univ Chicago, Sect Med Oncol, Chicago, IL 60637 USA

[10] Roswell Pk Canc Inst, NRG Oncol, Gynecol Oncol Grp, Biostat & Data Ctr, Buffalo, NY 14263 USA

[11] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA

来源：

GYNECOLOGIC ONCOLOGY | 2017年 / 146卷 / 02期

关键词：

PHASE-III TRIAL; OVEREXPRESSION; CARCINOMA; CHEMOTHERAPY; PROGNOSIS; PROLIFERATION; METASTASIS; MIGRATION; SUGGESTS; TUMORS;

D O I：

10.1016/j.ygyno.2017.05.017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective. Gynecologic Oncology Group (GOG) 177 demonstrated that addition of paclitaxel to a backbone of adriamycin/cisplatin improves overall survival (OS) and progression-free survival (PFS) for patients with advanced or recurrent endometrial cancer. Using patient specimens from GOG-177, our objective was to identify potential mechanisms underlying the improved clinical response to taxanes. Stathmin (STMN1) is a recognized poor prognostic marker in endometrial cancer that functions as a microtubule depolymerizing protein, allowing

引用

页码：247 / 253

页数：7

共 50 条

[1] FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
Jeske, Yvette W.
Ali, Shamshad
Byron, Sara A.
Gao, Feng
Mannel, Robert S.
Ghebre, Rahel G.
DiSilvestro, Paul A.
Lele, Shashikant B.
Pearl, Michael L.
Schmidt, Amy P.
Lankes, Heather A.
Ramirez, Nilsa C.
Rasty, Golnar
Powell, Matthew
Goodfellow, Paul J.
Pollock, Pamela M.
GYNECOLOGIC ONCOLOGY, 2017, 145 (02) : 366 - 373
[2] Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
McMeekin, D. Scott
Tritchler, David L.
Cohn, David E.
Mutch, David G.
Lankes, Heather A.
Geller, Melissa A.
Powell, Matthew A.
Backes, Floor J.
Landrum, Lisa M.
Zaino, Richard
Broaddus, Russell D.
Ramirez, Nilsa
Gao, Feng
Ali, Shamshad
Darcy, Kathleen M.
Pearl, Michael L.
DiSilvestro, Paul A.
Lele, Shashikant B.
Goodfellow, Paul J.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 3062 - +
[3] A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
Bender, David
Sill, Michael W.
Lankes, Heather A.
Reyes, Henry D.
Darus, Christopher J.
Delmore, James E.
Rotmensch, Jacob
Gray, Heidi J.
Mannel, Robert S.
Schilder, Jeanne M.
Hunter, Mark I.
McCourt, Carolyn K.
Samuelson, Megan I.
Leslie, Kimberly K.
GYNECOLOGIC ONCOLOGY, 2015, 138 (03) : 507 - 512
[4] Improving Risk Assessment for Metastatic Disease in Endometrioid Endometrial Cancer Patients Using Molecular and Clinical Features: An NRG Oncology/Gynecologic Oncology Group Study
Casablanca, Yovanni
Wang, Guisong
Lankes, Heather A.
Tian, Chunqiao
Bateman, Nicholas W.
Miller, Caela R.
Chappell, Nicole P.
Havrilesky, Laura J.
Wallace, Amy Hooks
Ramirez, Nilsa C.
Miller, David S.
Oliver, Julie
Mitchell, Dave
Litzi, Tracy
Blanton, Brian E.
Lowery, William J.
Risinger, John, I
Hamilton, Chad A.
Phippen, Neil T.
Conrads, Thomas P.
Mutch, David
Moxley, Katherine
Lee, Roger B.
Backes, Floor
Birrer, Michael J.
Darcy, Kathleen M.
Maxwell, George Larry
CANCERS, 2022, 14 (17)
[5] Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study
Felix, A. S.
Brasky, T. M.
Cohn, D. E.
Mutch, D. G.
Creasman, W. T.
Thaker, P. H.
Walker, J. L.
Moore, R. G.
Lele, S. B.
Guntupalli, S. R.
Downs, L. S.
Nagel, Ci
Boggess, J. F.
Pearl, M. L.
Ioffe, O. B.
Deng, W.
Miller, D. S.
Brinton, L. A.
INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (06) : 1102 - 1115
[6] Receipt of adjuvant endometrial cancer treatment updates according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study
Felix, Ashley S.
Cohn, David E.
Brasky, Theodore M.
Zaino, Richard
Park, Kay
Mutch, David G.
Creasman, William T.
Thaker, Premal H.
Walker, Joan L.
Moore, Richard G.
Lele, Shashikant B.
Guntupalli, Saketh R.
Downs, Levi S.
Nagel, Christa, I
Boggess, John F.
Pearl, Michael L.
Ioffe, Olga B.
Randall, Marcus E.
Brinton, Louise A.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2018, 219 (05) : 459.e1 - 459.e11
[7] Associations between etiologic factors and mortality after endometrial cancer diagnosis: The NRG Oncology/Gynecologic Oncology Group 210 trial
Felix, Ashley S.
McMeekin, D. Scott
Mutch, David
Walker, Joan L.
Creasman, William T.
Cohn, David E.
Ali, Shamshad
Moore, Richard G.
Downs, Levi S.
Ioffe, Olga B.
Park, Kay J.
Sherman, Mark E.
Brinton, Louise A.
GYNECOLOGIC ONCOLOGY, 2015, 139 (01) : 70 - 76
[8] Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
Krill, Lauren
Deng, Wei
Eskander, Ramez
Mutch, David
Zweizig, Susan
Hoang, Bang
Ioffe, Olga
Randall, Leslie
Lankes, Heather
Miller, David S.
Birrer, Michael
GYNECOLOGIC ONCOLOGY, 2020, 156 (02) : 423 - 429
[9] Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study
Olawaiye, Alexander B.
Java, James J.
Krivak, Thomas C.
Friedlander, Michael
Mutch, David G.
Glaser, Gretchen
Geller, Melissa
O'Malley, David M.
Wenham, Robert M.
Lee, Roger B.
Bodurka, Diane C.
Herzog, Thomas J.
Bookman, Michael A.
GYNECOLOGIC ONCOLOGY, 2018, 151 (01) : 18 - 23
[10] Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer: a validation study of the Gynecologic Oncology Group criteria
Kong, Tae Wook
Chang, Suk-Joon
Paek, Jiheum
Lee, Yonghee
Chun, Mison
Ryu, Hee-Sug
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2015, 26 (01) : 32 - +

← 1 2 3 4 5 →